Scarica l'app Stockscreener
7.16
8.81%
0.58
Dopo l'orario di chiusura:
7.11
-0.05
-0.70%
Clene Inc Borsa (CLNN) Ultime notizie
MSN Money - MSN
Clene Conference: CEO Says FDA Minutes Suggest CNM-Au8 Data Could Support ALS NDA Filing - Yahoo Finance
Analysts Are Bullish on Top Consumer Goods Stocks: BRC (BRCC), Clene (CLNN) - The Globe and Mail
CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment - MSN
Clene Inc. Announces Underwriting Agreement for 1,000,000 Shares of Common Stock on Nasdaq - Minichart
Clene Announces $7 Million Registered Direct Equity Offering - TipRanks
Ugwumba Chidozie sells $530,439 in Clene Inc. shares By Investing.com - Investing.com India
Ugwumba Chidozie sells $530,439 in Clene Inc. shares - Investing.com
SymBiosis II LLC, major Clene (NASDAQ: CLNN) holder, sells 78,679 shares - Stock Titan
Clene Incannounces common stock offeringSEC filing - marketscreener.com
Clene Inc. (NASDAQ: CLNN) files preliminary prospectus for common stock offering - Stock Titan
Clene (NASDAQ: CLNN) prices $7M stock sale to fund CNM-Au8 work - Stock Titan
Clene plans CNM-Au8 filing for accelerated approval in ALS - ALS News Today
Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug - Sahm
Clene Announces $7 Million Underwritten Offering of Common Stock - Investing News Network
Clene stock tumbles after pricing $7M stock offering By Investing.com - Investing.com Australia
Clene stock tumbles after pricing $7M stock offering - Investing.com UK
Clene announces $7 million underwritten offering of common stock - marketscreener.com
Clene to Present at Upcoming May Conferences - Investing News Network
Clene prices $7M stock offering to fund drug development - Investing.com
Clene prices $7M stock offering to fund drug development By Investing.com - Investing.com Australia
Clene Inc. Announces Pricing of $7 Million Registered Direct Offering of Common Stock - Quiver Quantitative
Clene sells 1M shares to fund ALS drug filing and Phase 3 trial - Stock Titan
Clene lines up May 6 webcast and New York investor meetings May 7 - Stock Titan
Symbiosis II LLC lists CLNN sales (NASDAQ: CLNN) including 67,991-share lot - Stock Titan
CLNN Maintained by D. Boral Capital -- Price Target Stays at $23 - GuruFocus
Clene Price Target Maintained With a $23.00/Share by D. Boral Capital - Moomoo
Clene Is Maintained at Buy by D. Boral Capital - Moomoo
CLNN Stock Holds Range As Insider Ownership Shifts - StocksToTrade
Clene provides update on NDA for ALS following Type C meeting with FDA - TipRanks
Clene Advances Towards NDA Submission for ALS Treatment (CLNN) - GuruFocus
Clene plans ALS drug application after FDA meeting By Investing.com - Investing.com South Africa
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Clene Stock Jumps After FDA Opens Door to Fast-Track ALS Drug Filing - TechStock²
Clene plans ALS drug application after FDA meeting - Investing.com UK
Clene Inc. to Submit Accelerated Approval NDA for ALS Drug CNM-Au8 Following Positive FDA Meeting - Minichart
CLNN Stock Holds Range As Insider Activity Draws Focus - timothysykes.com
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS - Investing News Network
Clene Advances CNM-Au8 Toward Accelerated ALS Approval - TipRanks
Clene stock surges 20% after FDA meeting on ALS drug approval By Investing.com - Investing.com South Africa
Clene plans ALS drug filing after FDA says data may support faster review - Stock Titan
Clene stock surges 20% after FDA meeting on ALS drug approval - Investing.com
After successful FDA meeting, Clene filing accelerated approval NDA for ALS - marketscreener.com
Clene (NASDAQ: CLNN) to file accelerated ALS drug NDA in 2026 - Stock Titan
Clene Inc. (NASDAQ:CLNN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):